Learn More-External Link
Trending at Lumira Ventures
Archemix Announces Continued Progress with Business Strategy
Company Achieves Key Clinical Milestone with Initiation of Phase 2b Trial for Lead Aptamer Product Candidate ARC1779 Company Announces Management Transition Plan January 27, 2009 02:00 PM Eastern Standard Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Archemix Corp., a privately-held biotechnology company working to …
Cardiac Dimensions(R) Inc. Announces Achievement of Implant Target for TITAN(TM) Safety Study
Learn More-External Link
Cephalon Signs Option Agreement to Acquire Ception Therapeutics
Learn More-External Link
U-Systems, Inc. announces technology licensing agreement with Siemens
Learn More-External Link
KAI Pharmaceuticals Initiates Phase 2b Clinical Study of KAI-9803 in Heart Attack Patients
Learn More-External Link
Millipore and Guava Technologies to Award Flow Cytometer Instrument
Learn More-External Link
KAI-1678, First-in-Class Compound, Enters Phase 2a Clinical Testing for the Treatment of Pain
Learn More-External Link